AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01400139
Drug: Hydrocodone bitartrate q24h film-coated tablets
RxNorm normalized name: hydrocodone
DrugBank: Hydrocodone (DB00956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
Trial: NCT04713436
Drug: Differentiation Markers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteocalcin (BGLAP), dentin sialo phosphoprotein (DSPP) and alkaline phosphatase (ALPP) gene expression levels were also evaluated.
Trial: NCT03425448
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin hemodialysis catheter lock solution
Trial: NCT01393600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution containing no active substance
Trial: NCT00850096
Drug: Nasulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
Trial: NCT02789475
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin administration
Trial: NCT02633930
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
Trial: NCT00433550
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given orally
Trial: NCT02653638
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. Transcranial Doppler~2. Blood Pressure~3. Heart Rate~4. Oxygen Saturation
Trial: NCT01373450
Drug: Oxyntomodulin
RxNorm normalized name: Oxyntomodulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
Trial: NCT02084576
Drug: Nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop in the study eye 3 times daily for 30 days
Trial: NCT02084576
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One drop in the study eye 4 times daily for 30 days
Trial: NCT04616105
Drug: REGN6490
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of REGN6490
Trial: NCT04616105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching single dose of REGN6490
Trial: NCT00361166
Drug: ACP-103
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00619164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally, once a day.
Trial: NCT02671825
Drug: PUR0200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUR0200 dry powder inhalation
Trial: NCT02671825
Drug: Reference Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry Powder Inhalation Reference Product
Trial: NCT00984061
Drug: clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
Trial: NCT03221140
Drug: Outpatient parenteral antimicrobial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of intravenous antimicrobials on an outpatient basis
Trial: NCT03607188
Drug: Alkotinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkotinib 200mg QD、 Alkotinib 300mg QD、 Alkotinib 400mg QD、 Alkotinib 500mg QD、 Alkotinib 600mg QD
Trial: NCT00460265
Drug: ARM 2
RxNorm normalized name: Surgitube Arm 2 5/8x50"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Cisplatin plus 5FU
Trial: NCT02289846
Drug: IW-9179
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289846
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02596126
Drug: Treatment Prevention for Secondary CV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
Trial: NCT00087542
Drug: ACP-103
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03160001
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
Trial: NCT01715610
Drug: Randomization to Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
Trial: NCT01715610
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to the antibiotic or placebo arm via a random number generator
Trial: NCT00425425
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03839771
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablets
Trial: NCT03839771
Drug: Placebo for AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg tablets
Trial: NCT03839771
Drug: Placebo for AG-221
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg tablets
Trial: NCT01886742
Drug: Standard Dose Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The standard dose of Cefazolin will be administered intravenously.
Trial: NCT01886742
Drug: Weight Based Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
Trial: NCT03573908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo oral capsule
Trial: NCT03386617
Drug: NEPA
RxNorm normalized name: cinepazet
DrugBank: Cinepazet (DB13342)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded.
Trial: NCT04212364
Drug: Narcan Nasal Product
RxNorm normalized name: Narcan Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All study participants will be trained in how to use nasal Narcan and they will receive a nasal Narcan kit.
Trial: NCT00130429
Drug: PYM50028
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01406522
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline cellulose
Trial: NCT00120107
Drug: Black Tea
RxNorm normalized name: black tea
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02178644
Drug: Chemo with concomitant Capecitabine and KD018
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
Trial: NCT03327389
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
Trial: NCT00189163
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill, taken orally, once per day, for 48 weeks
Trial: NCT02941796
Drug: HCP0918
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02941796
Drug: HCP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03027414
Drug: Transcranial Magnetic Stimulation Sham
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMS device is used to determine the effect of non-invasive brain stimulation on anxiety and anxiety-cognition interactions in healthy subjects.
Trial: NCT01782742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01953003
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arm A : 1650 mg/m² Arm B : 2500 mg/m²
Trial: NCT00791323
Drug: Ketorolac 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
Trial: NCT00791323
Drug: Lubricating Eye Drop
RxNorm normalized name: Ultra Lubricating Eye Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
Trial: NCT01799460
Drug: The Comprehensive Treatment Regimen of Traditional Chinese Medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day~②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.~③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily.
Trial: NCT00668135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01166490
Drug: ASG-5ME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
Trial: NCT00081796
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03644836
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweet taste cocoa flavored drink
Trial: NCT04134065
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the capsule contain nothing
Trial: NCT03685292
Drug: Behavioral Treatment
RxNorm normalized name: AspyreRx Digital Behavioral Therapeutic Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study addressed the efficacy of cognitive-behavioral therapy (CBT) treatment.
Trial: NCT03906721
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill used to condition patients.
Trial: NCT03724266
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intracanal medication
Trial: NCT00081731
Drug: Atacand/HCT, Caduet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacand/HCT and caduet or optimal medical therapy for hypertension
Trial: NCT00112281
Drug: Tilarginine Acetate Injection intravenous infusion
RxNorm normalized name: potassium acetate Injection
DrugBank: Potassium acetate (DB14498)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00861614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
Trial: NCT00847795
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01255592
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose bid
Trial: NCT01255592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose bid
Trial: NCT04462523
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.
Trial: NCT04462523
Drug: Topical Prednisolone
RxNorm normalized name: prednisolone Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care topical drop treatment
Trial: NCT01404208
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT00412217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo tablets (matched to erlotinib) once daily.
Trial: NCT00172354
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02691195
Drug: 0.9% Nacl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
Trial: NCT03704584
Drug: Control Group (corticosteroid alone)
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (corticosteroid alone) subjects will receive (40 mg/mL injection of Methylprednisolone acetate injectable suspension or 40 mg/mL triamcinolone) .
Trial: NCT01083641
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg oral three times daily
Trial: NCT01685853
Drug: PEG 4 litres split
RxNorm normalized name: PEG-4 diheptanoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * the day before colonoscopy: 2 litres of PEG~* the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination
Trial: NCT00006994
Drug: l-glutamine placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 cc three times daily for 60 days
Trial: NCT02607956
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 milligrams (mg) FDC tablets administered orally, once daily
Trial: NCT02607956
Drug: DTG Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally, once daily
Trial: NCT02607956
Drug: F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally, once daily
Trial: NCT02607956
Drug: B/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally, once daily
Trial: NCT01036932
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
Trial: NCT04048226
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in this group will be connected to the syringe pump that contain normal saline with starting infusion at a rate of 0.1 ml/kg/hr till the end of the surgery.
Trial: NCT01745835
Drug: 2L Coolprep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Trial: NCT00636168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Trial: NCT02691702
Drug: BIIB118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of BIIB118 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
Trial: NCT02691702
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
Trial: NCT01634295
Drug: CKD-828 2.5/40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Trial: NCT01634295
Drug: CKD-828 5/40mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.~* With the others investigation product placebo 4 tabs QD 2 weeks.
Trial: NCT01634295
Drug: CKD-828 5/80mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.~* With the others investigation product placebo 4 tabs QD 6 weeks.
Trial: NCT03166215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-935 placebo-matching tablets.
Trial: NCT03077659
Drug: NanoPac®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
Trial: NCT04453800
Drug: sofadil【Neu2000KW】
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 250mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Trial: NCT04453800
Drug: Sofadil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Trial: NCT04453800
Drug: Sofadil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500mg Intravenous infusion of sofadil starting at 500mg was 500ml，followed by nine intravenous infusions, each 500mg infusion with 250ml sofadil for 5 days, and each interval is 12 hours
Trial: NCT00782600
Drug: suspension IR
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg IR suspension once daily for one day
Trial: NCT00782600
Drug: CR 1
RxNorm normalized name: Paxil CR 12.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg shorter release CR once daily for one day
Trial: NCT00985959
Drug: JNJ-26866138 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
Trial: NCT00985959
Drug: JNJ-26866138 1.3 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
Trial: NCT00985959
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
Trial: NCT00981851
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
Trial: NCT02553707
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
Trial: NCT04676685
Drug: E2730-matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2730-matched placebo capsules.
Trial: NCT00002756
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002756
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002756
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03803228
Drug: Conventional stimuli
RxNorm normalized name: STIMULEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 stimulations by Fertistartkit® performed on 2 different cycles
Trial: NCT04907227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT03221088
Drug: Jintrolong® low dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
Trial: NCT02707952
Drug: ABT-493/ABT-530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-formulated tablet
Trial: NCT02707952
Drug: OBV/PTV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-formulated tablet
Trial: NCT00168506
Drug: CBT
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00168506
Drug: CBT/SSRI
FDA approved: no
EMA approved: no
PMDA approved: no